Corvus reports Q4 net loss $12.1M, cash $52M; atopic dermatitis Phase 1 shows 37% EASI 75 vs 0% placebo

Corvus Pharmaceuticals, Inc.

Net loss for Q4 2024 was $12.1M vs $6.7M in Q4 2023; full-year R&D expense $19.4M.
Cash, equivalents and securities $52.0M as of Dec 31, 2024, up from $27.1M, with runway into Q1 2026.
Atopic dermatitis Phase 1 cohorts 1-2: 26% of soquelitinib patients achieved IGA 0/1, 37% EASI 75 vs 0% placebo.
Phase 3 registrational trial of soquelitinib in PTCL is enrolling; Phase 2 ALPS trial initiated under NIAID.
Approximately $18.6M cash from early exercise of 5.3M warrants; 11.8M warrants remain outstanding.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.